Meperidine hydrochloride - Generic Drug Details
What are the generic sources for meperidine hydrochloride and what is the scope of patent protection?
Meperidine hydrochloride
is the generic ingredient in four branded drugs marketed by Hospira, Quagen, Abbott, Baxter Hlthcare, Igi Labs Inc, Intl Medication, Parke Davis, Watson Labs, West-ward Pharms Int, Icu Medical Inc, Specgx Llc, Hikma, Barr, Duramed Pharms Barr, Epic Pharma Llc, Genus, Strides Pharma Intl, Sun Pharm Inds Inc, Sun Pharm Industries, and Wyeth Ayerst, and is included in forty-five NDAs. Additional information is available in the individual branded drug profile pages.Four suppliers are listed for this compound.
Summary for meperidine hydrochloride
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 20 |
| NDAs: | 45 |
| Drug Master File Entries: | 4 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 78 |
| Patent Applications: | 4,758 |
| What excipients (inactive ingredients) are in meperidine hydrochloride? | meperidine hydrochloride excipients list |
| DailyMed Link: | meperidine hydrochloride at DailyMed |
Recent Clinical Trials for meperidine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cukurova University | NA |
| Ondokuz Mays University | NA |
| Tanta University | NA |
Pharmacology for meperidine hydrochloride
| Drug Class | Opioid Agonist |
| Mechanism of Action | Full Opioid Agonists |
Medical Subject Heading (MeSH) Categories for meperidine hydrochloride
US Patents and Regulatory Information for meperidine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| West-ward Pharms Int | MEPERIDINE HYDROCHLORIDE | meperidine hydrochloride | INJECTABLE;INJECTION | 080445-001 | Approved Prior to Jan 1, 1982 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Watson Labs | MEPERIDINE HYDROCHLORIDE | meperidine hydrochloride | TABLET;ORAL | 040186-002 | Jun 30, 1997 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Genus | MEPERIDINE HYDROCHLORIDE | meperidine hydrochloride | TABLET;ORAL | 040893-002 | Jun 24, 2009 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Genus | MEPERIDINE HYDROCHLORIDE | meperidine hydrochloride | TABLET;ORAL | 040893-003 | Jun 24, 2009 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Duramed Pharms Barr | MEPERIDINE HYDROCHLORIDE | meperidine hydrochloride | TABLET;ORAL | 040318-002 | Oct 5, 1999 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch